Im­mat­ics spikes on a round of promis­ing — but still ear­ly — au­tol­o­gous cell ther­a­py da­ta for sol­id tu­mors

Com­ing off some re­cent set­backs, Im­mat­ics is rolling out its lat­est up­date on a new ap­proach to sol­id tu­mors that’s bol­stered hopes and in­spired a spike in the share price of the Ger­man/US biotech as it rolls to­ward piv­otal work next year.

At first cut, the ob­jec­tive re­sponse rate was 80%, which slid to 64% (7) for the 11 pa­tients at week six in this sec­ond take of the da­ta for IMA203 TCR-T monother­a­py. Six of nine pa­tients (67%) with mul­ti­ple pre-treat­ed tu­mor types hit a con­firmed ORR at month three. That’s still well in the range that the com­pa­ny had hoped to hold the line, with ev­i­dence of dura­bil­i­ty that will be crit­i­cal to prove con­clu­sive­ly in the tri­al work ahead for the biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER